Stock Events

Stock Events

Dyadic International DE 

$0.000000
7
-$0.06-100% Friday 22:07

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

25MarExpected
Q3 2024
Q4 2024
Q2 2025
Q3 2025
Q4 2025
-0.07
-0.05
-0.03
-0.01
Expected EPS
-0.045
Actual EPS
N/A

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap233.78B
Amgen is a biotechnology company that competes with Dyadic in the development of biopharmaceuticals, leveraging advanced bioprocessing technologies.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is involved in biopharmaceuticals, directly competing with Dyadic in the field of drug development and biologic manufacturing.
Biogen
BIIB
Mkt Cap32.28B
Biogen competes with Dyadic in the biotechnology sector, focusing on the development of therapies for neurological diseases, utilizing advanced biologic production methods.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals is a competitor in the biotech industry, focusing on creating medicines for serious diseases, similar to Dyadic's focus on biopharmaceuticals.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is a research-based biopharmaceutical company that competes with Dyadic in developing and commercializing innovative therapeutics.
Adaptive Biotechnologies
ADPT
Mkt Cap4.02B
Adaptive Biotechnologies competes with Dyadic by focusing on the body's immune system to develop products for disease diagnosis and treatment.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is involved in gene editing, a cutting-edge area of biotechnology that competes with Dyadic's biopharmaceutical development efforts.
Editas Medicine
EDIT
Mkt Cap485.31M
Editas Medicine operates in the genome editing field, directly competing with Dyadic's efforts in leveraging biotechnology for therapeutic development.
Intellia Therapeutics
NTLA
Mkt Cap1.8B
Intellia Therapeutics is a competitor in the CRISPR/Cas9 technology space, relevant to Dyadic's work in biopharmaceuticals and gene therapies.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals competes with Dyadic in the development of RNAi therapeutics, a novel approach to treating disease.

About

Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
Show more...
CEO
Mark A. Emalfarb
Employees
5
Country
United States

Listings

XNAS
US
DYAI
BOATS
BOATS
DYAI.BOATS

0 Comments

Share your thoughts

FAQ

What is Dyadic International DE stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on AMEX exchange Dyadic International DE stocks are traded under the ticker DIL.
Is Dyadic International DE stock price growing?▼
DIL stock has risen by +0% compared to the previous week, the month change is a -12% fall, over the last year Dyadic International DE has showed a -66.75% decrease.
How many employees does Dyadic International DE have?▼
As of September 04, 2026, the company has 5 employees.
In which sector is Dyadic International DE located?▼
Dyadic International DE operates in the Health & Wellness sector.
When did Dyadic International DE complete a stock split?▼
Dyadic International DE has not had any recent stock splits.
Where is Dyadic International DE headquartered?▼
Dyadic International DE is headquartered in JUPITER, United States.